Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. New clinical guidelines
3. Managing cardiovascular risk factors
4. How do we define response at 1 year?
5. Benefits of 10 kg weight loss
6. Why to treat pharmacologically? (1)
7. Weight loss and cardiovascular risk
8. Why to treat pharmacologically? (2)
9. What is success in weight management?
10. Why to treat pharmacologically? (3)
11. The STORM study on body weight changes
12. Characteristics ideal anti-obesity agent (1 )
13. Topiromate has a dose-dependent effect
14. Characteristics ideal anti-obesity agent (2)
15. Drug therapy - for whom to consider?
16. Previous drugs used in obesity treatment
17. Previous experience with anti-obesity drugs
18. Recent experience with anti-obesity drugs
19. Sibutramine has dual physiological action
20. Sibutramine has a dual transmitter effect
21. Pharmacology of centrally acting agents
22. Normal neural function
23. Different mode of action for centrally acting drugs
24. Weight loss at endpoint
25. Patients obtaining a weight loss >10% in 1 year
26. STORM study: 8 European centres
27. STORM study: body weight changes over 2 years
28. Intensified behavioural and dietary intervention
29. Leisure activity contributes to weight maintenance
30. Recent experience with anti-obesity drugs: Orlistat
31. Physiology of fat absorption
32. Orlistat inhibits lipase activity
33. Lipase inhibition: mechanism of action
34. Orlistat can inhibit absorption of 30% of dietary fat
35. 1-year weight loss with orlistat
36. % of patients who achieved meaningful weight loss
37. Sub-analysis of orlistat studies
38. Post-absorptive nutrient partitioning
39. Involvement of cannabinoid system
40. Cannabinoid (CB) receptors
41. Sites of CB1 receptors and effects of its blockade
42. Rimonabant - the first CB1 blocker
43. Changes in weight and waist
44. Change in HDL-cholestrol and triglycerides
45. Changes in leptin and adiponectin
46. Body weight changes with CB1-blockade
47. Future experience to be made
48. Drugs altering energy intake
49. Time course of body weight with exenatides
50. Drugs and their extra "beyond" benefits (1)
51. Effect of orlistat on LDL-cholesterol
52. Change in LDL-cholesterol after 1 year
53. The STORM study and lipid changes
54. Effects of sibutramine on HDL
55. Improvements in lipid parameters with rimonabant
56. Improvement in fasting insulin/insulin resistance
57. Pharmacotherapy and diabetes
58. Overweight type II diabetic vs. non-diabetic
59. Weight loss in diabetic and non diabetic patients
60. Initial weight loss of >5% / 10% in orlistat patients
61. Weight/waist perimeter changes (diabetic patients)
62. Drugs and their extra "beyond" benefits (2)
63. XENDOS study objectives
64. Changes in body weight in XENDOS trial
65. Cumulative incidence of type II diabetes
66. Orlistat - side effects
67. Sibutramine - side effects
68. Rimonabant - side effects
69. Time for action

Topics Covered

• Pharmacotherapy as target for 5 to 10 % weight loss option
• Pharmacotherapy as an additional approach for weight management programs
• Characteristics of appropriate anti-obesity agents
• Actual experience with anti-obesity agents
• Potential new agents for the future
• Metabolic "beyond weight loss" effects
• Safety

Links

Series:

• Obesity

Categories:

• Clinical Practice
• Metabolism & Nutrition

Therapeutic Areas:

• Cardiovascular & Metabolic

Talk Citation

Van Gaal, L. (2007, October 1). New standards in weight management: recent and future drugs for the treatment of obesity [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/BZUB6713.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Archived on February 25, 2021

Financial Disclosures

• Prof. Luc Van Gaal has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.